USRE29842E - Untriakontapeptide with opiate activity - Google Patents
Untriakontapeptide with opiate activity Download PDFInfo
- Publication number
- USRE29842E USRE29842E US05/822,772 US82277277A USRE29842E US RE29842 E USRE29842 E US RE29842E US 82277277 A US82277277 A US 82277277A US RE29842 E USRE29842 E US RE29842E
- Authority
- US
- United States
- Prior art keywords
- lys
- obr
- boc
- thr
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/675—Beta-endorphins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin
Definitions
- Peptide-like substances having morphine like activity derived from bovine and porcine pituitaries have been reported by Goldstein and coworkers. Life Sciences, 16, 1775 (1975). Hughes et al. have suggested that these substances may be the peptide fragments derived from enzymatic digests of beta-lipoprotein.
- the present invention relates to a untriakontapeptide having the following sequence:
- the untriakontapeptide of the present invention has an amino acid sequence identical to the COOH-terminal 31 residues of bovine beta-lipotropin.
- the first five amino acid residues of the NH 2 -terminal have the identical sequence of the Hughes et al. pentapeptide.
- beta-endorphin For purposes of convenience the untriakontapeptide of this invention shall hereafter be referred to as beta-endorphin.
- beta-endorphin from natural sources can be carried out utilizing procedures well known in the art.
- Preferred natural sources for this material include ovine pituitary glands, preferably camel pituitaries.
- fraction D whole camel pituitaries are subjected to acid acetone extraction to yield fraction D which in turn is chromatographed on a CM-cellulose column to provide component N as described by Li et al, Biochemistry 14, 947 (1975).
- component N Purification of component N is accomplished by utilizing gel filtration and electrophoresis procedures known per se to thereby yield the desired .[.beta-endophine.]. .Iadd.beta-endorphine..Iaddend.
- Identification of the amino acid content and sequence of beta-endorphin can be obtained by enzymatic digestion of the beta-endorphin derived from purified component N using trypsin and subtilsin digestion in a conventional manner. The digests are then mapped by paper chromatography followed by high voltage electrophoresis. After developing of the spots with ninhydrin and elution, it is found that the trypsin digestion produces 11 spots while the subtilsin digestion yields 10 spots. The spots are eluted and the amino acid content determined by an automatic analyzer while the amino acid sequence is determined by the dansyl-Edman procedure. Utilization of such procedures resulted in the determination that beta-endorphin is an untriakontapeptide having an amino acid content and sequence as set forth above.
- beta-endorphin can be carried out employing solid phase techniques now well known in the art.
- amino protected glutamine representing the --COOH terminal group of beta-endorphin
- a conventional solid phase peptide synthesis resin such as benzyhydrylamine polystyrene cross-linked with 1 to 2% divinyl benzene.
- the amino protecting group is then selectively removed utilizing a suitable reagent whose nature will depend on the protecting group used.
- the t-butyloxycarbonyl (Boc) group is utilized for amino group protection and 50% trifluoroacetic acid in methylene chloride is the selective deprotecting agent.
- the glutamine-resin is treated with amino protected glycine, preferably N-boc-glycine, most preferably as the preformed symmetrical anhydride of N-Boc-glycine in a manner known per se as to form a peptide bond between the free amino group of the glutamine residue and the carboxyl group of glycine.
- amino protected glycine preferably N-boc-glycine, most preferably as the preformed symmetrical anhydride of N-Boc-glycine in a manner known per se as to form a peptide bond between the free amino group of the glutamine residue and the carboxyl group of glycine.
- oBr-Z, Bzl and Boc are as above and ® is the .[.styrene-% .]. .Iadd.styrene-1% .Iaddend. divinylbenzene copolymer.
- Decoupling of the peptide from the resin is accomplished by treatment with liquid hydrogen fluoride with concomittant cleavage of all protecting group to produce the desired beta-endorphin.
- beta-endorphin has the amino acid sequence of residue 61-91 of beta-lipotropin hormone the lipolytic activity of beta-endorphin is very low in comparison to the complete hormone.
- beta-endorphin has significant opiate agonist activity and this is useful as a potent, non-addictive analgesic agent.
- Synthetic and natural beta-endorphin have identical physical and biological properties.
- a further aspect of the present invention relates to analogs of beta-endorphin which correspond to the amino acid sequence found in corresponding beta-lipotropin from porcine and human hormone.
- the instant invention relates to untriakontapeptides of the following formula:
- X is Ile or Val; Y is His or Tyr and Z is Gln or Glu.
- the above compounds are conveniently prepared by conventional solid phase peptide synthesis in analogy to that described for beta-endorphin by substitution of the appropriate alternate amino acid in this synthesis.
- the compounds of the present invention can be used as medicaments in the form of pharmaceutical preparations having direct or delayed liberation of the active ingredient which contain them in association with a compatible pharmaceutical carrier material.
- This carrier material can be an organic or inorganic inert carrier material suitable for enteral, percutaneous or parenteral application such as water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkyleneglycols, petroleum jelly, etc.
- the pharmaceutical preparations can be made up in a solid form (e.g., as tablets, dragees, suppositories or capsules), in a semi-solid form (e.g., as salves) or in a liquid form (e.g., as solutions, suspensions or emulsions). If necessary the pharamceutical preparations can be sterilized and/or contain adjuvant substances such as preserving, stabilizing, wetting or emulsifying agents, salts for the variation of the osmotic pressure or substances acting as buffers.
- adjuvant substances such as preserving, stabilizing, wetting or emulsifying agents, salts for the variation of the osmotic pressure or substances acting as buffers.
- a compound of the invention in the case of pharmaceutical preparations for systemic administration, about 5 to 750 mg/kg of a compound of the invention can be provided per administration.
- the pharmaceutical preparations can be prepared in a manner known per se by mixing a compound of the invention with non-toxic solid and/or liquid carrier materials which are customary in pharmaceutical preparations and which are suitable for therapeutic administration (e.g., those carrier materials mentioned earlier) and, if desired, transforming the mixture into the desired pharmaceutical dosage form.
- non-toxic solid and/or liquid carrier materials which are customary in pharmaceutical preparations and which are suitable for therapeutic administration (e.g., those carrier materials mentioned earlier) and, if desired, transforming the mixture into the desired pharmaceutical dosage form.
- Fraction C was further purified by preparative electrophoresis on Whatman No. 3 MM paper in pyridine-acetic acid buffer of pH 3.7 (pyridine-HoAc-H 2 O: 4/40/1150; v/v) for 2 hours at 400 V.
- the major band was eluted with 0.1 N acetic acid and lyopholized to yield 7.5 mg. of pure product.
- NH 2 -terminal analysis of this material gave only tyrosine as the end group.
- Enzyme digestions of the product of Example 1 were performed with 1 mg. of peptide and 0.02 mg. trypsin or 0.05 mg. subtilsin in pH 8.0 buffer (0.2 M ammonium acetate) at 37° C. for 8 hours in the case of trypsin and 1 hour for subtilsin.
- the digests were mapped by paper chromatography (butanol/acetic acid/water: 4/1/5 (v/v)) and subsequent high voltage electrophoresis at pH 2.0 [formic acid (88%)/acetic acid/water: 218/63/719 (v/v)] for 1.5 hr. at 200 V. Maps were sprayed with 1% ninhydrin in ethanol solution and allowed to develop in the dark for 20 hours.
- beta-endorphin The sequence of beta-endorphin is derived from the data set forth in Table 1 of Example 1 and Tables 2 and 3 of this Example. As shown in Table 1, arginine, cystine and tryptophan are absent from component N-Fraction C. In addition, this material has only one residue each of histidine, glutamic acid, valine, methionine and tyrosine. Since the NH 2 -terminal residue is tyrosine, tryptic peptide T8 must be located at the NH 2 - terminus. From the amino acid and NH 2 - terminal data of subtilsin peptide S9 (Table 2) it is apparent that T8 is linked to T9. Similarly, S7 can provide the overlap for T9 and T7.
- Peptide T6 has COOH-terminal glutamine and no lysine, it may be assumed to be located at the COOH-terminus.
- Peptide T5 indicates the probability of Lys-Lys linkage and this is confirmed by T1 and T3 (Tables 2 and 3).
- Peptide T1 also serves to link T3 and T5.
- the arrangement of hyptic peptides is as follows; T8 ⁇ T9 ⁇ T7 ⁇ T3 ⁇ T5 and the complete amino acid sequence of Component N-Fraction C (beta-endorphin) is as set forth previously in the specification for the untriakontapeptide.
- Boc-amino acids with dicyclohexylcarbodiimide was performed as follows: 1.9 mmol of Boc-amino acid in 6 ml. of methylene chloride were cooled to 0° C. and mixed with 1.6 ml. of 0.6 M N,N'-dicyclohexylcarbodiimide in methylene chloride. After stirring for 20 minutes at 0° C., the precipitate of dicyclohexylurea was removed by filtration at 25° C. and washed with 2.4 ml. of methylene chloride. The filtrate was used immediately for the coupling reaction.
- the resin just described was submitted to the following synthesis schedule: 1. Wash with three 15 ml. portions of methylene chloride (retention volume of the resin for methylene chloride was 5 ml. after filtation); (2) removal of the Boc group with 50% trifluoroacetic acid in methylene chloride for 15 min; (3) wash with two 15 ml. portions of methylene chloride; (4) wash with two 15 ml. portions of 50% dioxane in methylene chloride; (5) wash with two 15 ml. portions of methylene chloride; (6) five minutes of neutralization with 15 ml. of 5% diiosopropylethylamine in methylene chloride; (7) wash with six 15 ml.
- beta-endorphin has a potent opiate agonist activity; its potency being 3.42 times that for normophine on a molar basis.
- the lypolytic activity of natural beta-endorphin was compared to the activity of ovine beta-lipotropin hormone in rabbit fat cells using the procedure of Li et al., Arch. Biochem. Biophys. 169, 669 (1975). The results obtained are summarized in Table 5.
- Beta-endorphin Analogous to Sequence Porcine Beta-lipotropin
- Example 3 The procedure of Example 3 is repeated with the exception that the first Boc-Ile amino acid is substituted with Boc-Val so as to thereby produce an analog of beta-endorphin having an amino acid sequence of the corresponding section of porcine beta-lipotropin
- Beta-endorphin Analogous to Sequence Human Beta-lipotropin
- Example 3 The procedure of Example 3 is repeated with the exception that the carboxyl terminus group utilized is Boc-Glu(Bzl) .[.and.]., Boc-His(Bc) is replaced by Boc-Tyr(oBr-Z) .Iadd.and a conventional copolystyrene-divinylbenzene resin is selected, e.g., chloromethylated copolystyrene-divinylbenzene .Iaddend.to thereby produce an analog of beta-endorphin having an amino acid sequence as follows:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An untriakontapeptide having significant opiate agonist activity has been isolated from camel pituitary glands. The structure of this peptide has been determined and this peptide was then synthesized utilizing solid phase peptide synthesis. Both natural and synthetic material show identical physical and biological properties.
Description
Hughes et al. Nature 258, 557 (1975), have described the isolation of a pentapeptide, H-Tyr-Gly-Gly-Phe-Met-OH- from pig brains. The pentapeptide exhibits opiate agonist activity.
This amino acid sequence occurs as residues 61 to 65 of ovine beta-lipotropin. See the papers by Li and coworkers, Nature 208, 1093 (1965); Excerpta Medica Internatl. Congr. Ser. 112, 349 (1966); and Biochem. Biophys. Res. Commun. 53, 1304 (1973).
Peptide-like substances having morphine like activity derived from bovine and porcine pituitaries have been reported by Goldstein and coworkers. Life Sciences, 16, 1775 (1975). Hughes et al. have suggested that these substances may be the peptide fragments derived from enzymatic digests of beta-lipoprotein.
The present invention relates to a untriakontapeptide having the following sequence:
H-tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-His-Lys-Lys-Gly-Gln-OH.
this material has been isolated from camel pituitary extracts and after sequencing has been synthesized utilizing classical solid phase synthesis procedures. Both the natural and synthetic peptides process significant opiate agonist activity and very low lipotropic activity.
It is of interest to note that the untriakontapeptide of the present invention has an amino acid sequence identical to the COOH-terminal 31 residues of bovine beta-lipotropin. In addition, the first five amino acid residues of the NH2 -terminal have the identical sequence of the Hughes et al. pentapeptide.
For purposes of convenience the untriakontapeptide of this invention shall hereafter be referred to as beta-endorphin.
The isolation of beta-endorphin from natural sources can be carried out utilizing procedures well known in the art. Preferred natural sources for this material include ovine pituitary glands, preferably camel pituitaries.
Thus, for example, whole camel pituitaries are subjected to acid acetone extraction to yield fraction D which in turn is chromatographed on a CM-cellulose column to provide component N as described by Li et al, Biochemistry 14, 947 (1975).
Purification of component N is accomplished by utilizing gel filtration and electrophoresis procedures known per se to thereby yield the desired .[.beta-endophine.]. .Iadd.beta-endorphine..Iaddend.
Identification of the amino acid content and sequence of beta-endorphin can be obtained by enzymatic digestion of the beta-endorphin derived from purified component N using trypsin and subtilsin digestion in a conventional manner. The digests are then mapped by paper chromatography followed by high voltage electrophoresis. After developing of the spots with ninhydrin and elution, it is found that the trypsin digestion produces 11 spots while the subtilsin digestion yields 10 spots. The spots are eluted and the amino acid content determined by an automatic analyzer while the amino acid sequence is determined by the dansyl-Edman procedure. Utilization of such procedures resulted in the determination that beta-endorphin is an untriakontapeptide having an amino acid content and sequence as set forth above.
Synthesis of beta-endorphin can be carried out employing solid phase techniques now well known in the art. In a preferred procedure amino protected glutamine, representing the --COOH terminal group of beta-endorphin, is coupled to a conventional solid phase peptide synthesis resin such as benzyhydrylamine polystyrene cross-linked with 1 to 2% divinyl benzene. The amino protecting group is then selectively removed utilizing a suitable reagent whose nature will depend on the protecting group used. In the preferred embodiment the t-butyloxycarbonyl (Boc) group is utilized for amino group protection and 50% trifluoroacetic acid in methylene chloride is the selective deprotecting agent.
After deprotection, the glutamine-resin is treated with amino protected glycine, preferably N-boc-glycine, most preferably as the preformed symmetrical anhydride of N-Boc-glycine in a manner known per se as to form a peptide bond between the free amino group of the glutamine residue and the carboxyl group of glycine.
The cycle of deprotection and coupling with the preformed symmetrical anhydrides of protected amino acids is then repeated with the remaining amino acids in the sequence order of beta-endorphin. Some of the amino acids required side-chain blocking groups besides the alpha-amino protection. Such amino acids and the blocking groups employed are as follows:
Glu(OBzl), Ser(Bzl), Lys(oBr-Z) Tyr(oBr-Z) and His(Boc)
wherein oBr-Z is ortho bromo-benzyloxycarbonyl, Bzl is benzyl and Boc is as above.
Completion of the synthesis provided the following protected untriakontapeptide coupled to the styrenedivinylbenzene copolymer resin:
Boc-Tyr-(oBr-Z)-Gly-Gly-Phe-Met-Thr-Ser(Bzl)-Glu(OBzl)-Lys(oBr-Z)-Ser(Bzl)-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys(oBr-Z)-Asn-Ala-Ole-Ile-Lys-(oBr-Z)-Asn-Ala-His(Boc)-Lys(oBr-Z)-Lys-(oBr)-Gly-Gln-®
wherein oBr-Z, Bzl and Boc are as above and ® is the .[.styrene-% .]. .Iadd.styrene-1% .Iaddend. divinylbenzene copolymer.
Decoupling of the peptide from the resin is accomplished by treatment with liquid hydrogen fluoride with concomittant cleavage of all protecting group to produce the desired beta-endorphin.
In spite of the fact that beta-endorphin has the amino acid sequence of residue 61-91 of beta-lipotropin hormone the lipolytic activity of beta-endorphin is very low in comparison to the complete hormone. However, beta-endorphin has significant opiate agonist activity and this is useful as a potent, non-addictive analgesic agent. Synthetic and natural beta-endorphin have identical physical and biological properties.
A further aspect of the present invention relates to analogs of beta-endorphin which correspond to the amino acid sequence found in corresponding beta-lipotropin from porcine and human hormone. Thus in its broadest aspect the instant invention relates to untriakontapeptides of the following formula:
H-tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-X-Lys-Asn-Ala-Y-Lys-Lys-Gly-Z-OH
wherein X is Ile or Val; Y is His or Tyr and Z is Gln or Glu.
The above compounds are conveniently prepared by conventional solid phase peptide synthesis in analogy to that described for beta-endorphin by substitution of the appropriate alternate amino acid in this synthesis.
The compounds of the present invention can be used as medicaments in the form of pharmaceutical preparations having direct or delayed liberation of the active ingredient which contain them in association with a compatible pharmaceutical carrier material. This carrier material can be an organic or inorganic inert carrier material suitable for enteral, percutaneous or parenteral application such as water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkyleneglycols, petroleum jelly, etc. The pharmaceutical preparations can be made up in a solid form (e.g., as tablets, dragees, suppositories or capsules), in a semi-solid form (e.g., as salves) or in a liquid form (e.g., as solutions, suspensions or emulsions). If necessary the pharamceutical preparations can be sterilized and/or contain adjuvant substances such as preserving, stabilizing, wetting or emulsifying agents, salts for the variation of the osmotic pressure or substances acting as buffers.
In the case of pharmaceutical preparations for systemic administration, about 5 to 750 mg/kg of a compound of the invention can be provided per administration.
The pharmaceutical preparations can be prepared in a manner known per se by mixing a compound of the invention with non-toxic solid and/or liquid carrier materials which are customary in pharmaceutical preparations and which are suitable for therapeutic administration (e.g., those carrier materials mentioned earlier) and, if desired, transforming the mixture into the desired pharmaceutical dosage form.
Isolation of Natural Beta-Endorphin
A total of 500 whole camel pituitary glands was extracted with acid acetone according to the procedure of Li et al. Biochemistry 14, 947 (1975) to provide fraction D. Chromatography of fraction D on a CM-cellulose column yielded 66 mg. of component N.
Gel filtration of the 66 mg. of component N on a Sephadex G-25 (fine) column in 0.1 N acetic acid. Six fractions were obtained with the following yields after lyophilization:
A-10 mg; B-7 mg; C-11 mg; D-13 mg; E-2 mg. and F-7 mg.
Fraction C was further purified by preparative electrophoresis on Whatman No. 3 MM paper in pyridine-acetic acid buffer of pH 3.7 (pyridine-HoAc-H2 O: 4/40/1150; v/v) for 2 hours at 400 V. The major band was eluted with 0.1 N acetic acid and lyopholized to yield 7.5 mg. of pure product. NH2 -terminal analysis of this material gave only tyrosine as the end group.
Amino acid analysis as carried out on a sample of the pure product according to Spackman et al., Anal. Chem. 30, 1190 (1958), utilizing an automatic analyzer. The resulting amino acid composition of this product is set forth in Table 1.
Table 1 ______________________________________ Amino Acid Composition of Peptide Component N-Fraction C Amino From Acid From the Acid Hydrolysates.sup.a Sequence ______________________________________ Lysine 5.1 5 Histidine 0.9 1 Aspartic Acid 2.0 2.sup.b Threonine 3.2 3 Serine 1.6 2 Glutamic acid 2.7 3.sup.c Proline 0.7 1 Glycine 3.2 3 Alanine 1.7 2 Valine 0.9 1 Methionine 0.6 1 Isoleucine 1.0.sup.d 2 Leucine 2.0 2 Tyrosine 0.9 1 Phenylalanine 1.9 2 ______________________________________ .sup.a Acid hydrolyses were carried out for 24 hr. at 110° with 6 HCl. .sup.b Two asparagine. .sup.c Sum of one glutamic acid and two glutamine. .sup.d 72 hr. hydrolysis revealed the presence of two residues.
The absence of tryptophan was ascertained by color test on paper according to the procedure of Smith, Nature VII 43 (1953).
Structure Determination
Enzyme digestions of the product of Example 1 were performed with 1 mg. of peptide and 0.02 mg. trypsin or 0.05 mg. subtilsin in pH 8.0 buffer (0.2 M ammonium acetate) at 37° C. for 8 hours in the case of trypsin and 1 hour for subtilsin. The digests were mapped by paper chromatography (butanol/acetic acid/water: 4/1/5 (v/v)) and subsequent high voltage electrophoresis at pH 2.0 [formic acid (88%)/acetic acid/water: 218/63/719 (v/v)] for 1.5 hr. at 200 V. Maps were sprayed with 1% ninhydrin in ethanol solution and allowed to develop in the dark for 20 hours. The spots were cut out and eluted with 0.1 N ammonium hydroxide solution. The eluates were dried in the dissicator for amino acid and sequence analyses. Amino acid analysis was carried out according to Spackman et al. supra. The amino acid sequence of peptides was determined by the dansyl-Edman procedure as described by Li et al., Arch. Biochem. Biophys. 141, 705 (1970). The determination of Asp/Asn and Glu/Gln was deduced from the mobility on paper electrophoresis at pH 6.7 according to Offord, Nature 211, 591 (1966). The results are summarized in Tables 2 and 3 below.
Table 2 ______________________________________ Amino Acid Composition.sup.2 and Amino-terminal Residue of Trypic and Subtilisn Peptides from Component N-Fraction C Subtilisin Amino Tryptic Peptides Peptides Acid T1 T3 T5 T6 T7 T8 T9 S7 S9 ______________________________________ Lys 2.2 1.1 0.9 1.0 1.0 1.0 1.1 1.0 His 0.9 1.0 Asp 1.0 0.6 0.8 1.0 Thr 1.1 2.1 1.0 Ser 1.0 0.8 1.1 Glu 1.1 1.0 1.0 1.2 1.8 Pro 0.8 1.1 Gly 1.0 0.5 2.0 Ala 1.0 0.8 1.1 0.8 Val 1.0 Met 0.8 He 2.0 2.0 Leu 2.2 1.0 Tyr 0.6 Phe 1.0 0.9 NH.sub.2 -- Asn Asn Lys Gly Asn Tyr Ser Lys Glu (term.) ______________________________________ Results from 6 N HCl hydrolysates at 110° C for 24 hr. except for T7 and S7 which were hydrolyzed in 72 hr.
Table 3 ______________________________________ Sequence Analysis on Tryptic Peptide Derivatives from Component N-Fraction C Peptides.sup.a Sequence.sup.b ______________________________________ T8 Tyr--Gly--Gly--Phe--Met--Thr--Ser--Glu--Lys →→.fwdarw .→→→→→ T9 Ser--Gln--Thr--Pro--Leu--Val--Thr--Leu-- →→→.f wdarw.→→→→ --Phe--Lys → T7 Asn--Ala--Ile--Ile--Lys →→→→ T3 Asn--Ala--His--Lys →→→ T5 Lys--Gly--Gln →→→ T6 Gly--Gln →→ ______________________________________ .sup. a See Table 2 for amino acid analysis. .sup.b →, dansyl-Edman procedure
The sequence of beta-endorphin is derived from the data set forth in Table 1 of Example 1 and Tables 2 and 3 of this Example. As shown in Table 1, arginine, cystine and tryptophan are absent from component N-Fraction C. In addition, this material has only one residue each of histidine, glutamic acid, valine, methionine and tyrosine. Since the NH2 -terminal residue is tyrosine, tryptic peptide T8 must be located at the NH2 - terminus. From the amino acid and NH2 - terminal data of subtilsin peptide S9 (Table 2) it is apparent that T8 is linked to T9. Similarly, S7 can provide the overlap for T9 and T7.
Peptide T6 has COOH-terminal glutamine and no lysine, it may be assumed to be located at the COOH-terminus. Peptide T5 indicates the probability of Lys-Lys linkage and this is confirmed by T1 and T3 (Tables 2 and 3). Peptide T1 also serves to link T3 and T5. Thus it may be concluded that the arrangement of hyptic peptides is as follows; T8→T9→T7→T3→T5 and the complete amino acid sequence of Component N-Fraction C (beta-endorphin) is as set forth previously in the specification for the untriakontapeptide.
Solid Phase Synthesis of Beta-endorphin
N.sup.α -boc-α-Benzyl-γ-Glutamyl Benzhydrylamine Resin
Attachment of α-benzyl N.sup.α -t-butoxycarbonyl glutamate to benzhydrylamine resin was performed by means of its symmetrical anhydride. A sample (2.5 g.) of benzhydrylamine hydrochloride resin containing 0.38 mmol free amine per g. was neutralized with 5% diisopropylethylamine (DIEA) in CH2 Cl2 and then treated with 3 equivalents of the symmetrical anhydride in CH2 Cl2 for 45 min. Five ml. of 5% DIEA in CH2 Cl2 were then added followed by an additional 10 min. reaction time. The reaction was terminated by filtration and washings with three 30 ml. portions of CH2 Cl2 and three 30 ml. portions of absolute ethanol. After retreatment of the resin with the same amount of symmetrical anhydride, it was dried in vacuo over P2 O5 for 1 hour. Completeness of the reaction was verified by the Gisin test. After hydrolysis of a sample in propionic acid-12 N HCl, amino acid analysis gave one peak corresponding to 0.23 mmol of Gln per g. (68% cleavage). The identification of the HF cleaved product as glutamine was confirmed by thin layer chromatography in 1-butanol-acetic acid-water (4:1:1) and 1-butanol-pyridine-acetic acid-water (6:6:1.2:4.6).
Symmetrical Anhydrides of Boc-Amino Acids
The reaction of Boc-amino acids with dicyclohexylcarbodiimide was performed as follows: 1.9 mmol of Boc-amino acid in 6 ml. of methylene chloride were cooled to 0° C. and mixed with 1.6 ml. of 0.6 M N,N'-dicyclohexylcarbodiimide in methylene chloride. After stirring for 20 minutes at 0° C., the precipitate of dicyclohexylurea was removed by filtration at 25° C. and washed with 2.4 ml. of methylene chloride. The filtrate was used immediately for the coupling reaction.
Protected Beta-Endorphin Benzhydrylamine Resin
The resin just described was submitted to the following synthesis schedule: 1. Wash with three 15 ml. portions of methylene chloride (retention volume of the resin for methylene chloride was 5 ml. after filtation); (2) removal of the Boc group with 50% trifluoroacetic acid in methylene chloride for 15 min; (3) wash with two 15 ml. portions of methylene chloride; (4) wash with two 15 ml. portions of 50% dioxane in methylene chloride; (5) wash with two 15 ml. portions of methylene chloride; (6) five minutes of neutralization with 15 ml. of 5% diiosopropylethylamine in methylene chloride; (7) wash with six 15 ml. portions of methylene chloride; (8) add the solution of preformed symmetrical anhydride of Boc-amino acid and shake for 30 min; (9) add .20 equivalents of 5% diisopropylethylamine in methylene chloride and shake for another 20 min; (10) wash with three 15 ml. portions of methylene chloride; and (11) wash with three 15 ml. portions of absolute ethanol. The above cycle was repeated for the following N-protected amino acids:
Boc-Gly
Boc-Lys(oBr-Z)
Boc-Lys(oBr-Z)
Boc-His(Boc)
Boc-Ala
Boc-Asn
Boc-Lys(oBr-Z)
Boc-Ile
Boc-Ile
Boc-Ala
Boc-Asn*
Boc-Lys(oBr-Z)
Boc-Phe
Boc-Leu
Boc-Thr
Boc-Val
Boc-Leu
Boc-Pro
Boc-Thr
Boc-Gln
Boc-Ser(Bzl)
Boc-Lys(oBr-Z)
Boc-Glu(OBzl)
Boc-Ser(Bzl)
Boc-Thr
Boc-Met
Boc-Phe
Boc-Gly
Boc-Gly
Boc-Tyr(oBR-Z)
β-Endorphin
A sample (0.6 g.) of protected endorphin resin was submitted to deprotection and neutralization steps in order to remove the Boc group. The dried resin was then stirred in the presence of 1.8 ml. of anisole and 15 ml. of liquid HF at 0° C. for 1 hour. The HF was removed with a stream of nitrogen and the oily residue was washed with two 15-ml. portions of ethyl acetate. The peptide was extracted from the resin with three 15-ml. portions of 50% acetic acid and the combined filtrates were evaporated in vacuo to a small volume (3 to 5 ml.) and submitted to gel filtration on Sephadex G-10(2 × 25 cm column) in 0.5 N acetic acid. One peak (280 nm detection) was detected and lyophilization gave 110 mg. This material was then submitted to chromatography on carboxymethylcellulose. Isolation of th main peak (280 nm detection) gave 66 mg. of material. Further purification of this material was effected by partition chromatography on Sephadex G-50. Isolation of the material represented by the main peak [Folin-Lowry detection] (RF = 0.21) gave 52 mg. of highly purified beta-endorphin (19.6% yield based on the starting resin).
On thin layer chromatography (BPAW), the purified material (50 μg) gave one spot (ninhydrin detection) with an RF value of 0.35. On paper electrophoresis, synthetic beta-endorphin (50 μg samples) gave a single spot at both pH 3.7 and 6.9 with respective RF values (relative to Lys) of 0.65 and 0.42. Gel electrophoresis of the purified material (100 μg) also gave a single band at pH 4.5 for 1 hour. A sample (1 mg) was also submitted to electrofocusing in 5% polyacrylamide gel. Only one band (detection by precipitation with 12% trichloroacetic acid) was observed with an approximate pI of 10.0. Amino acid analysis after acid hydrolysis gave: Lys5.2, HiS0.9, Asp2.2, Thr3.0, Ser2.1, Glu2.1, Pro1.1, Gly3.0, Ala2.1, Val1.1 Met0.9, Ile1.5, Leu2.2, Tyr1.0, and Phe2.2. Amino acid analysis after complete enzymic digestion (first with trypsin and chymotrypsin, and then leucine amino peptidase) gave: Lys3.0, His1.0, Thr3.2, (Ser, Asn, Gln)3.2, Glu1.1, Pro0.9, Gly3.0, Ala2.1, Val1.0, Met1.2, Ile2.0, Leu2.1, Tyr1.1 and Phe1.8.
Biological Activity of Beta-Endorphin
The opiate agonist activity of natural beta-endophine was determined by the method of Simon et al., Proc. Nat. Acad. Sci. 70, 1947 (1973) using guinea pig brain membranes. The results obtained are summarized below in Table 4:
Table 4 ______________________________________ Opiate Agonist Activity of β.sub.s -LPH-(61 - 91) by Receptic Binding Assay Dose Preparation (10-.sup.7 M) Response.sup.a ______________________________________ Normophine 0.7 28 ± 0.8 7.0 70 ± 0.9 β.sub.s -LPH-(61 - 91).sup.b 1.0 60 ± 0.7 10.0 83 ± 0.2 ______________________________________ .sup.a Percentage of inhibition of stereospecific binding. Mean ± standard error from 4 determinations. .sup.b Relative potency to normorphine, 342% with a 95% confidence limit of 300 - 392 and λ = 0.044.
It is seen from the above Table that beta-endorphin has a potent opiate agonist activity; its potency being 3.42 times that for normophine on a molar basis.
The lypolytic activity of natural beta-endorphin was compared to the activity of ovine beta-lipotropin hormone in rabbit fat cells using the procedure of Li et al., Arch. Biochem. Biophys. 169, 669 (1975). The results obtained are summarized in Table 5.
Table 5 ______________________________________ Lipolytic Activity of β-lipotropin hormone and natural β-endorphin Preparation Dose Response.sup.a ______________________________________ Beta-lipotropin hormone 0.37 3.24 ± 0 1.1 5.71 ± 19 natural beta-endorphine 1.1 0.66 ± 0.28 10.0 1.42 ± 0.37 control 0 0.74 ± 0.06 ______________________________________ .sup.a Micromole of glycerol production per gram of cells per hour. Determinations in triplicate. Values in mean ± standard error.
Analog of Beta-endorphin Analogous to Sequence Porcine Beta-lipotropin
The procedure of Example 3 is repeated with the exception that the first Boc-Ile amino acid is substituted with Boc-Val so as to thereby produce an analog of beta-endorphin having an amino acid sequence of the corresponding section of porcine beta-lipotropin
H-tyr-Gly-.Iadd.Gly.Iaddend.-Phe-Met-Thr-Ser-Glu-Lys-Ser-.Iadd.Gln.Iaddend.-Thr-Pro-Leu-Val-Thr Leu-Phe-Lys-Asn-Ala-Ile-Val-Lys Asn-Ala-His-Lys-Lys-Gly-Gln-OH
Analog of Beta-endorphin Analogous to Sequence Human Beta-lipotropin
The procedure of Example 3 is repeated with the exception that the carboxyl terminus group utilized is Boc-Glu(Bzl) .[.and.]., Boc-His(Bc) is replaced by Boc-Tyr(oBr-Z) .Iadd.and a conventional copolystyrene-divinylbenzene resin is selected, e.g., chloromethylated copolystyrene-divinylbenzene .Iaddend.to thereby produce an analog of beta-endorphin having an amino acid sequence as follows:
H-tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu-OH
which corresponds to that portion of the human beta-lipotropin.
Claims (7)
1. A compound of the formula
Boc-Tyr(oBr-Z)-Gly-Gly-Phe-Met-Thr-Ser(Bzl)-Glu(OBzl)-Lys(oBr-Z)-Ser(Bzl)-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys(oBr-Z)-Asn-Ala-Ile Ile-Lys-(oBr-Z)-Asn-Ala-His(Boc)-Lys(oBr-Z)-Lys(oBr-X)-Gly-Gln®
wherein oBr-Z is ortho bromobenzyloxycarbonyl; Bzl is benzyl; Boc is .[.toxycarbonyl.]. .Iadd.t-butyloxycarbonyl and ® is styrene-divinyl-benzene copolymer resin.
2. A compound of the formula
H-tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-X-Lys-Asn-Ala-Y-Lys-Lys-Gly-Z-OH
wherein X is Ile or Val; Y is His or Tyr and Z is Gln or Glu said compound being essentially free of other biogenic peptides.
3. The compound of claim .[.4.]. .Iadd.2 .Iaddend.wherein X is Ile; Y is His and Z is Gln.
4. The compound of claim 2 wherein X is Val; Y is His and Z is Gln.
5. The compound of claim 2 wherein X is Ile; Y is Tyr and Z is Glu.
6. A compound of the formula
Boo-Tyr(oBr-Z)-Gly-Gly-Phe-Met-Thr-Ser(Bzl)-Glu(OBzl)-Lys-(oBr-Z)-Ser(BZl)-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys(oBr-Z)-Ans-Ala-Ile-Val-Lys-(oBr-Z)-Asn-Ala-His(Boc)-Lys(oBr-Z)-Lts(oBr-Z)-Glyn-Gln®
wherein OBr-Z is orthobromobenzyloxycarbonyl; Bzl is benzyl; Boc is t-butyloxcarbonyl and ® is styrene-divinylbenzene copolymer resin.
7. A compound of the formula:
Boc-Tyr(oBr-Z)-Gly-Gly-Phe-Me-Thr-Ser(Bzl)-Glu-(OBzl)-Lys-(oBr-Z)-Ser(Bzl)-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys(oBr-Z)-Asn-Ala-Ile-Ile-Lys-(oBrZ)-Asn-Ala-Tyr(oBr-Z)-Lys-(oBr-Z)-Lys(oBr-Z)-Gly-Glu(Bzl)®
wherein oBr-Z is orthobromobenzyloxycarbonyl; Bzl is benzyl; Boc is t-butyloxycarbonyl and ® is styrene-divinylbenzene copolymer resin.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/667,747 US4038222A (en) | 1976-03-17 | 1976-03-17 | Untriakontapeptide with opiate activity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US05/667,747 Reissue US4038222A (en) | 1976-03-17 | 1976-03-17 | Untriakontapeptide with opiate activity |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE29842E true USRE29842E (en) | 1978-11-21 |
Family
ID=24679466
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US05/667,747 Expired - Lifetime US4038222A (en) | 1976-03-17 | 1976-03-17 | Untriakontapeptide with opiate activity |
US05/822,772 Expired - Lifetime USRE29842E (en) | 1976-03-17 | 1977-08-08 | Untriakontapeptide with opiate activity |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US05/667,747 Expired - Lifetime US4038222A (en) | 1976-03-17 | 1976-03-17 | Untriakontapeptide with opiate activity |
Country Status (26)
Country | Link |
---|---|
US (2) | US4038222A (en) |
JP (1) | JPS52113958A (en) |
AR (2) | AR222778A1 (en) |
AT (1) | AT355238B (en) |
AU (1) | AU514499B2 (en) |
BE (1) | BE852510A (en) |
CA (1) | CA1092602A (en) |
CH (1) | CH625785A5 (en) |
DE (1) | DE2711487C2 (en) |
DK (1) | DK149203C (en) |
ES (2) | ES456901A1 (en) |
FI (1) | FI63391C (en) |
FR (1) | FR2348912A1 (en) |
GB (1) | GB1563654A (en) |
GR (1) | GR63092B (en) |
IE (1) | IE44226B1 (en) |
IL (1) | IL51660A (en) |
LU (1) | LU76963A1 (en) |
MC (1) | MC1137A1 (en) |
NL (1) | NL7702849A (en) |
NO (1) | NO147105C (en) |
NZ (1) | NZ183605A (en) |
PH (1) | PH13864A (en) |
PT (1) | PT66311B (en) |
SE (1) | SE436354B (en) |
ZA (1) | ZA771593B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4396606A (en) | 1979-11-05 | 1983-08-02 | Addiction Research Foundation | Novel polypeptide analgesics |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4320117A (en) * | 1976-06-21 | 1982-03-16 | Imperial Chemical Industries Limited | Polypeptide |
US4123523A (en) * | 1976-06-21 | 1978-10-31 | Imperial Chemical Industries Limited | Analgesic and sedative polypeptides |
US4371463A (en) * | 1977-02-17 | 1983-02-01 | The United States Of America As Represented By The Department Of Health And Human Services | Enzyme-resistant opiate pentapeptides |
US4081434A (en) * | 1977-03-11 | 1978-03-28 | Hoffmann-La Roche Inc. | Novel analogs of β-endorphin |
US4317770A (en) * | 1977-03-11 | 1982-03-02 | Hoffmann-La Roche Inc. | D-amino acid analogs of beta-endorphin |
US4098781A (en) * | 1977-03-11 | 1978-07-04 | American Home Products Corporation | Polypeptides with morphine-like activity |
US4127522A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel triacontapeptides, intermediates therefor and pharmaceutical compositions and methods employing said triacontapeptides |
US4127528A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel derivatives of alpha-endorphin, intermediates therefor and compositions and methods employing said derivatives |
US4127518A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel derivatives of gamma-endorphins, intermediates therefor, and compositions and methods employing said derivatives |
US4127532A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel heptapeptides, intermediates therefor, and compositions and methods employing said heptapeptides |
US4127536A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tricosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said tricosapeptides |
US4127526A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tetradecapeptides, intermediates therefor, and compositions and methods employing said tetradecapeptides |
US4127523A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel undecapeptides, intermediates therefor, and compositions and methods employing said undecapeptides |
US4127541A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel decapeptides, intermediates therefor, and compositions and methods employing said decapeptides |
US4127537A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tetracosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said tetracosapeptides |
US4127520A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel nonadecapeptides, intermediates therefor, and compositions and methods employing said nonadecapeptides |
US4127517A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel docosapeptides, intermediates therefore and pharmaceutical compositions and methods employing said docosapeptides |
ZA783287B (en) * | 1977-06-16 | 1980-01-30 | D Coy | Novel polypeptides |
US4127533A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel octapeptides, intermediates therefor, and compositions and methods employing said octapeptides |
US4127534A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tripeptides, intermediates therefor and pharmaceutical compositions and methods employing said tripeptides |
US4127538A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel pentacosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said pentacosapeptides |
US4127540A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel derivatives of δ-endorphins, intermediates therefor, and compositions and methods employing said derivatives |
US4127525A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tridecapeptides, intermediates therefor, and compositions and methods employing said tridecapeptides |
US4127521A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel octacosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said octacosapeptides |
US4127530A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel heneicosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said heneicosapeptides |
US4127519A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Octadecapeptides, intermediates therefor, and compositions and methods employing said octadecapeptides |
US4127527A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel pentadecapeptides, intermediates therefor, and compositions and methods employing said pentadecapeptides |
US4312857A (en) * | 1977-06-16 | 1982-01-26 | The United States Of America As Represented By The Veterans Administration | Novel derivatives of beta-endorphin, intermediates therefor and compositions and methods employing said derivatives |
US4127524A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel dodecapeptides, intermediates therefor, and compositions and methods employing said dodecapeptides |
US4139504A (en) * | 1977-06-16 | 1979-02-13 | Coy David Howard | Novel nonapeptides, intermediates therefor, and compositions and methods employing said nonapeptides |
US4127535A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel dipeptides, intermediates therefor, and compositions and methods employing said dipeptides |
US4127531A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel hexapeptides, intermediates therefor, and compositions and methods employing said hexapeptides |
US4127529A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel eicosapeptides, intermediates therefor and pharmaceutical compositions and methods employing said eicosapeptides |
US4127539A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel hexacosapeptides, intermediates therefore and pharmaceutical compositions and methods employing said hexacosapeptides |
US4105652A (en) * | 1977-08-05 | 1978-08-08 | Hoffmann-La Roche Inc. | Synthesis of human β-endorphin |
US4232008A (en) * | 1978-11-17 | 1980-11-04 | Ortho Pharmaceutical Corporation | Tetrapeptides and methods |
US4116950A (en) * | 1978-01-16 | 1978-09-26 | Hoffmann-La Roche Inc. | Analogs of human β-endorphin |
US4330465A (en) * | 1978-03-02 | 1982-05-18 | Hoffmann-La Roche Inc. | Novel β-endorphin analogs |
US4219468A (en) * | 1978-11-13 | 1980-08-26 | Hoffmann-La Roche Inc. | Tritiated β-endorphin |
US4250087A (en) * | 1979-12-10 | 1981-02-10 | Hoffmann-La Roche Inc. | Carboxyl terminus analogs of β-endorphin |
JPS56108750A (en) * | 1980-02-01 | 1981-08-28 | Takeda Chem Ind Ltd | Polypeptide and its preparation |
US4438104A (en) | 1980-01-03 | 1984-03-20 | Endorphin, Inc. | Endorphins having placental or pancreatic origin |
US4316895A (en) * | 1980-01-03 | 1982-02-23 | Kimball Charles D | Endorphins having placental or pancreatic origin |
US4350764A (en) * | 1980-03-10 | 1982-09-21 | The Regents Of The University Of California | Microbiological synthesis of beta endorphin |
US4313937A (en) * | 1980-08-12 | 1982-02-02 | Tsutomu Oyama | Method for producing long-lasting analgesic effects of β-endorphin |
GB2111505B (en) * | 1981-06-16 | 1984-09-26 | Charles D Kimball | Endorphins having placental or pancreatic origin |
FR2857873B1 (en) * | 2003-07-21 | 2006-02-24 | Courtage Et De Diffusion Codif | METHOD AND COSMETIC PRODUCT FOR LIMITING THE GROWTH OF ADIPOSE TISSUES |
-
1976
- 1976-03-17 US US05/667,747 patent/US4038222A/en not_active Expired - Lifetime
-
1977
- 1977-02-16 CH CH193477A patent/CH625785A5/de not_active IP Right Cessation
- 1977-03-06 AU AU23298/77A patent/AU514499B2/en not_active Expired
- 1977-03-09 MC MC771235A patent/MC1137A1/en unknown
- 1977-03-15 CA CA274,024A patent/CA1092602A/en not_active Expired
- 1977-03-15 NZ NZ183605A patent/NZ183605A/en unknown
- 1977-03-15 PH PH19558A patent/PH13864A/en unknown
- 1977-03-15 FR FR7707621A patent/FR2348912A1/en active Granted
- 1977-03-15 IL IL51660A patent/IL51660A/en unknown
- 1977-03-16 NL NL7702849A patent/NL7702849A/en not_active Application Discontinuation
- 1977-03-16 ZA ZA00771593A patent/ZA771593B/en unknown
- 1977-03-16 ES ES456901A patent/ES456901A1/en not_active Expired
- 1977-03-16 DK DK116177A patent/DK149203C/en not_active IP Right Cessation
- 1977-03-16 BE BE175818A patent/BE852510A/en not_active IP Right Cessation
- 1977-03-16 PT PT66311A patent/PT66311B/en unknown
- 1977-03-16 JP JP2815177A patent/JPS52113958A/en active Granted
- 1977-03-16 LU LU76963A patent/LU76963A1/xx unknown
- 1977-03-16 AR AR266874A patent/AR222778A1/en active
- 1977-03-16 SE SE7703004A patent/SE436354B/en not_active IP Right Cessation
- 1977-03-16 NO NO770941A patent/NO147105C/en unknown
- 1977-03-16 AT AT178877A patent/AT355238B/en not_active IP Right Cessation
- 1977-03-16 FI FI770835A patent/FI63391C/en not_active IP Right Cessation
- 1977-03-16 GB GB11109/77A patent/GB1563654A/en not_active Expired
- 1977-03-16 IE IE571/77A patent/IE44226B1/en unknown
- 1977-03-16 DE DE2711487A patent/DE2711487C2/en not_active Expired
- 1977-03-17 GR GR53010A patent/GR63092B/en unknown
- 1977-08-08 US US05/822,772 patent/USRE29842E/en not_active Expired - Lifetime
- 1977-11-25 AR AR270126A patent/AR222007A1/en active
-
1978
- 1978-03-01 ES ES467453A patent/ES467453A1/en not_active Expired
Non-Patent Citations (2)
Title |
---|
Bradbury, et al., "Proceedings of 4th Annual Amer. Peptide Sympossium, 1975". * |
li, et al., Biochemistry 14, pp. 947-952, 1975. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4396606A (en) | 1979-11-05 | 1983-08-02 | Addiction Research Foundation | Novel polypeptide analgesics |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE29842E (en) | Untriakontapeptide with opiate activity | |
Li et al. | Isolation and structure of an untriakontapeptide with opiate activity from camel pituitary glands. | |
Schwabe et al. | Primary structure of the B-chain of porcine relaxin | |
EP0561412B1 (en) | Parathyroid hormone derivatives | |
Minamino et al. | β-Neo-endorphin, a new hypothalamic “big” Leu-enkephalin of porcine origin: Its purification and the complete amino acid sequence | |
CA1270598A (en) | Growth hormone releasing factor analogs and process therefore | |
Ling et al. | Solid phase synthesis of somatostatin-28 | |
JP2679786B2 (en) | Method for synthesizing peptide having non-peptide bond | |
USRE34165E (en) | Potent thymopentin analogs | |
Yamashiro et al. | Synthesis of a pentekontapeptide with high lipolytic activity corresponding to the carboxyl-terminal fifty amino acids of ovine β-lipotropin | |
Ling | Solid phase synthesis of porcine α-endorphin and γ-endorphin, two hypothalamic-pituitary peptides with opiate activity | |
US4081434A (en) | Novel analogs of β-endorphin | |
CA1255850A (en) | Peptides with disulfide bridges and method | |
TZOUGRAKI et al. | SYNTHESIS OF HUMAN β‐ENDORPHIN IN SOLUTION USING BENZYL‐TYPE SIDE CHAIN PROTECTIVE GROUPS | |
KHAN et al. | SYNTHESIS OF THE DODECAPEPTIDE‐α MATING FACTOR OF SACCHAROMYCES CEREVISIAE | |
CA1108122A (en) | Protected coupled hentriakontapeptide intermediates | |
US4264492A (en) | Enkephalin-like compounds in bovine adrenal medulla | |
IE64494B1 (en) | Cyclic grf-analogs | |
Boissonnas et al. | Chemistry of the neurohypophysial hormones | |
Huang et al. | The Primary Structure of Staphylococcal Enterotoxin B: I. ISOLATION, COMPOSITION, AND SEQUENCE OF TRYPTIC PEPTIDES FROM OXIDIZED ENTEROTOXIN B | |
Li et al. | β-endorphin: Replacement of glutamic acid in position 8 by glutamine increases analgesic potency and opiate receptor-binding activity | |
BLAKE et al. | β‐ENDORPHIN: SYNTHESIS AND RADIOLIGAND BINDING ACTIVITY OF ANALOGS CONTAINING CYSTINE BRIDGES | |
US4639509A (en) | [16,19-Di-alanine] calcitonin | |
KR810000736B1 (en) | Process for preparing hentriakonta peptides | |
DANHO et al. | [A19-Phenylalanine] Insulin: A New Synthetic Analogue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE, 2200 Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:HOFFMAN-LAROCHE INC.;REEL/FRAME:004060/0025 Effective date: 19821104 |